NCT03188731

Brief Summary

The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations. We will estimate the absolute and relative risks of congenital malformations and other adverse outcomes of pregnancy among women who become infected with ZIKV during pregnancy compared to uninfected pregnant women, also leading to further validation of the Congenital Zika Syndrome.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3,852

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2017

Longer than P75 for all trials

Geographic Reach
7 countries

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 24, 2017

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

June 13, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 15, 2017

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

May 24, 2022

Status Verified

May 1, 2022

Enrollment Period

4.4 years

First QC Date

June 13, 2017

Last Update Submit

May 17, 2022

Conditions

Keywords

ZIKADengueChikungunyaPregnant WomenPregnant WomanZIKV

Outcome Measures

Primary Outcomes (1)

  • Congenital Abnormalities

    At birth

Study Arms (1)

Pregnant Women

Eligibility Criteria

Age16 Years - 45 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

Pregnant Women

You may qualify if:

  • at least 16 years old
  • Pregnancy status confirmed
  • Within first or second trimester or first month of marked transmission season

You may not qualify if:

  • Planing to leave area
  • Unable to attend follow-up visits
  • Unable to undergo venipuncture
  • Participates in another pregnant women study for ZIKA
  • Unable to consent without legal guardian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Sosecali Ltd. (SOSE)

Guaqui, Bolivia

Location

INSERM

Santa Cruz, Bolivia

Location

Federal University of Bahia (UFB)

Bahia, Brazil

Location

Universidade Federal de Minas Gerais

Belo Horizonte, Brazil

Location

Federal University of Goias

Goiás, Brazil

Location

Fundacao Oswaldo Cruz (FIOCRUZ)

Recife, Brazil

Location

Fundacao Oswaldo Cruz (FIOCRUZ)

Rio de Janeiro, Brazil

Location

University of Sao Paulo

São Paulo, Brazil

Location

Industrial University of Santander (UIS)

Bucaramanga, Colombia

Location

Pedro Kouri Institute (IPK)

Havana, Cuba

Location

INSERM

Pointe-à-Pitre, Guadeloupe

Location

IMSS Mexico (IMSS)

Guadalajara, Mexico

Location

National Institute of Public Health (INSP)

Mérida, Mexico

Location

Universidad de Carabobo / UMC Groningen (UMCG)

Valencia, Venezuela

Location

Related Publications (1)

  • Avelino-Silva VI, Mayaud P, Tami A, Miranda MC, Rosenberger KD, Alexander N, Nacul L, Segurado A, Pohl M, Bethencourt S, Villar LA, Viana IFT, Rabello R, Soria C, Salgado SP, Gotuzzo E, Guzman MG, Martinez PA, Lopez-Gatell H, Hegewisch-Taylor J, Borja-Aburto VH, Gonzalez C, Netto EM, Saba Villarroel PM, Hoen B, Brasil P, Marques ETA, Rockx B, Koopmans M, de Lamballerie X, Jaenisch T; ZIKAlliance Clinical Study Group. Study protocol for the multicentre cohorts of Zika virus infection in pregnant women, infants, and acute clinical cases in Latin America and the Caribbean: the ZIKAlliance consortium. BMC Infect Dis. 2019 Dec 26;19(1):1081. doi: 10.1186/s12879-019-4685-9.

Biospecimen

Retention: SAMPLES WITH DNA

Blood, Hair, Urine, Vaginal fluids, Saliva, Semen

MeSH Terms

Conditions

Zika Virus InfectionDengueChikungunya Fever

Condition Hierarchy (Ancestors)

Mosquito-Borne DiseasesVector Borne DiseasesInfectionsArbovirus InfectionsVirus DiseasesFlavivirus InfectionsFlaviviridae InfectionsRNA Virus InfectionsHemorrhagic Fevers, ViralAlphavirus InfectionsTogaviridae Infections

Study Officials

  • Thomas Jänisch

    University Hospital Heidelberg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Scientist

Study Record Dates

First Submitted

June 13, 2017

First Posted

June 15, 2017

Study Start

May 24, 2017

Primary Completion

September 30, 2021

Study Completion

September 30, 2021

Last Updated

May 24, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will share

1. The ZIKAlliance birth cohort is part of the 3 EC-funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published. 2. The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published.

Shared Documents
STUDY PROTOCOL, SAP, ICF

Locations